219 related articles for article (PubMed ID: 23964628)
1. The future of antimicrobial therapy in the era of antibiotic resistance in cystic fibrosis pulmonary infection.
McCaughey G; Gilpin D; Elborn J; Tunney MM
Expert Rev Respir Med; 2013 Aug; 7(4):385-96. PubMed ID: 23964628
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients.
Ciofu O; Tolker-Nielsen T; Jensen PØ; Wang H; Høiby N
Adv Drug Deliv Rev; 2015 May; 85():7-23. PubMed ID: 25477303
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis.
Sherrard LJ; Tunney MM; Elborn JS
Lancet; 2014 Aug; 384(9944):703-13. PubMed ID: 25152272
[TBL] [Abstract][Full Text] [Related]
4. The relevance of the polymicrobial nature of airway infection in the acute and chronic management of patients with cystic fibrosis.
Sibley CD; Parkins MD; Rabin HR; Surette MG
Curr Opin Investig Drugs; 2009 Aug; 10(8):787-94. PubMed ID: 19649923
[TBL] [Abstract][Full Text] [Related]
5. A retrospective analysis of biofilm antibiotic susceptibility testing: a better predictor of clinical response in cystic fibrosis exacerbations.
Keays T; Ferris W; Vandemheen KL; Chan F; Yeung SW; Mah TF; Ramotar K; Saginur R; Aaron SD
J Cyst Fibros; 2009 Mar; 8(2):122-7. PubMed ID: 19064337
[TBL] [Abstract][Full Text] [Related]
6. The cystic fibrosis airway microbiome.
Rabin HR; Surette MG
Curr Opin Pulm Med; 2012 Nov; 18(6):622-7. PubMed ID: 22965275
[TBL] [Abstract][Full Text] [Related]
7. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Greally P; Whitaker P; Peckham D
Curr Med Res Opin; 2012 Jun; 28(6):1059-67. PubMed ID: 22401602
[TBL] [Abstract][Full Text] [Related]
8. Cystic fibrosis lung microbiome: opportunities to reconsider management of airway infection.
Caverly LJ; Zhao J; LiPuma JJ
Pediatr Pulmonol; 2015 Oct; 50 Suppl 40():S31-8. PubMed ID: 26335953
[TBL] [Abstract][Full Text] [Related]
9. Antibiotic synergy testing should not be routine for patients with cystic fibrosis who are infected with multiresistant bacterial organisms.
Aaron SD
Paediatr Respir Rev; 2007 Sep; 8(3):256-61. PubMed ID: 17868924
[TBL] [Abstract][Full Text] [Related]
10. Antibiotic use in cystic fibrosis.
Eisenberg JD
Curr Opin Pulm Med; 1996 Nov; 2(6):439-46. PubMed ID: 9363182
[TBL] [Abstract][Full Text] [Related]
11. Is there a role for antimicrobial stewardship in cystic fibrosis?
Waters VJ; Ratjen FA
Ann Am Thorac Soc; 2014 Sep; 11(7):1116-9. PubMed ID: 25102101
[TBL] [Abstract][Full Text] [Related]
12. Influence of the lung microbiome on antibiotic susceptibility of cystic fibrosis pathogens.
Vandeplassche E; Tavernier S; Coenye T; Crabbé A
Eur Respir Rev; 2019 Jun; 28(152):. PubMed ID: 31285289
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary infections in children with cystic fibrosis.
Stutman HR; Marks MI
Semin Respir Infect; 1987 Sep; 2(3):166-76. PubMed ID: 3317617
[TBL] [Abstract][Full Text] [Related]
14. [Current microbiological data on lower respiratory tract infection in cystic fibrosis. Part I: Isolated microorganisms and their clinical significance].
Coman G; Petraru E; Dahorea C; Anton DT
Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):580-7. PubMed ID: 23077957
[TBL] [Abstract][Full Text] [Related]
15. Cysteamine (Lynovex®), a novel mucoactive antimicrobial & antibiofilm agent for the treatment of cystic fibrosis.
Charrier C; Rodger C; Robertson J; Kowalczuk A; Shand N; Fraser-Pitt D; Mercer D; O'Neil D
Orphanet J Rare Dis; 2014 Nov; 9():189. PubMed ID: 25433388
[TBL] [Abstract][Full Text] [Related]
16. Antibiotic treatment of CF lung disease: from bench to bedside.
Bals R; Hubert D; Tümmler B
J Cyst Fibros; 2011 Jun; 10 Suppl 2():S146-51. PubMed ID: 21658633
[TBL] [Abstract][Full Text] [Related]
17. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008.
Emerson J; McNamara S; Buccat AM; Worrell K; Burns JL
Pediatr Pulmonol; 2010 Apr; 45(4):363-70. PubMed ID: 20232473
[TBL] [Abstract][Full Text] [Related]
18. Pathophysiology and management of pulmonary infections in cystic fibrosis.
Gibson RL; Burns JL; Ramsey BW
Am J Respir Crit Care Med; 2003 Oct; 168(8):918-51. PubMed ID: 14555458
[TBL] [Abstract][Full Text] [Related]
19. Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection.
Govan JR; Brown AR; Jones AM
Future Microbiol; 2007 Apr; 2(2):153-64. PubMed ID: 17661652
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in the microbiology of respiratory tract infection in cystic fibrosis.
Foweraker J
Br Med Bull; 2009; 89(1):93-110. PubMed ID: 19155262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
